UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 78

Sortiert nach

Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216)

Journal of clinical oncology, 2022-10, Vol.40 (28), p.3301-3309

2022

Volltextzugriff (PDF)

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer

Therapeutic Advances in Urology, 2023-01, Vol.15, p.17562872231182219-17562872231182219

2023

Volltextzugriff (PDF)

Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma

The oncologist (Dayton, Ohio), 2023-02, Vol.28 (2), p.157-164

2023

Volltextzugriff (PDF)

The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Real-World Multi-Institutional Analysis

The Journal of urology, 2022-07, Vol.208 (1), p.71-79

2022

Volltextzugriff (PDF)

Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma

The Journal of clinical investigation, 2024-07, Vol.134 (14), p.1-11

2024

Volltextzugriff (PDF)

Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles

The Journal of clinical investigation, 2024-06, Vol.134 (11), p.1-9

2024

Volltextzugriff (PDF)

Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors

Urologic oncology, 2022-10, Vol.40 (10), p.454-454.e16

2022

Volltextzugriff (PDF)

Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus (SAGE): Results of a Phase II Trial

The Journal of urology, 2020-09, Vol.204 (3), p.101097JU0000000000001065-537

2020

Volltextzugriff (PDF)

Evolving landscape of the treatment of metastatic clear cell renal cell carcinoma

Clinical advances in hematology & oncology, 2018-10, Vol.16 (10), p.677-686

2018

Volltextzugriff (PDF)

Survival outcomes in patients with muscle-invasive bladder cancer receiving neoadjuvant chemotherapy stratified by number of cycles

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4586-4586

2023

Volltextzugriff (PDF)

Real-world outcomes in patients with metastatic clear cell renal cell carcinoma receiving front-line axitinib plus pembrolizumab versus ipilimumab plus nivolumab

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4551-4551

2021

Volltextzugriff (PDF)

Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who receive second-line immunotherapy

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4535-4535

2021

Volltextzugriff (PDF)

Identifying strategies to address obstacles to optimal integration of cancer immunotherapies in the community

Journal of clinical oncology, 2020-02, Vol.38 (5_suppl), p.96-96

2020

Volltextzugriff (PDF)

Prime-boost immunotherapeutic trial in men with biochemical recurrence after definitive local therapy for prostate cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS5119-TPS5119

2023

Volltextzugriff (PDF)

Safety and efficacy of neoadjuvant chemotherapy (NAC) with accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (aMVAC) in patients (pts) with muscle invasive bladder cancer (MIBC) as a function of age

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.506-506

2020

Volltextzugriff (PDF)

A phase II trial of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.438-438

2023

Volltextzugriff (PDF)

Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5074-5074

2023

Volltextzugriff (PDF)

Multi-center, retrospective study of first-line systemic therapy ± immune checkpoint inhibition for metastatic neuroendocrine carcinoma of the urinary tract

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.467-467

2023

Volltextzugriff (PDF)

Bicalutamide with or without metformin for biochemical recurrence in prostate cancer patients (BIMET-1)

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.85-85

2020

Volltextzugriff (PDF)

Role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4582-4582

2021

Volltextzugriff (PDF)

The evolution of clinical trials in renal cell carcinoma: A status report for 2013-2016 from the clinicaltrials.gov website

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e16050-e16050

2017

Volltextzugriff (PDF)

Safety of Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer and Malignant Ureteral Obstruction

BJU international, 2021-04, Vol.129 (3), p.364-372

2021

Volltextzugriff (PDF)

A phase I/II study of nivolumab and axitinib in patients with advanced renal cell carcinoma

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.291-291

2022

Volltextzugriff (PDF)

Phase I/II study of axitinib (axi) and nivolumab (nivo) in patients with metastatic renal cell carcinoma (mRCC)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.4567-4567

2019

Volltextzugriff (PDF)

1 – 25 von 78

Suche als RSS-Feed

Aktive Filter

ThemaCisplatin

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(77)
Mit Volltextzugriff
(67)

Publikationsform

Artikel
(78)

Sprache

Englisch
(78)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(33)
Life Sciences & Biomedicine
(32)
Humans
(23)
Oncology
(21)
Immunotherapy
(16)
Urology & Nephrology
(13)
Male
(8)
Metastasis
(8)
Kidney Neoplasms - Pathology
(7)
Renal Cell Carcinoma
(7)
Antineoplastic Agents - Therapeutic Use
(6)
Clinical Trials As Topic
(6)
Tumors
(6)
Aged
(5)
Bladder Cancer
(5)
Carcinoma, Renal Cell - Pathology
(5)
Kidney Cancer
(5)
Carcinoma, Renal Cell
(4)
Carcinoma, Renal Cell - Therapy
(4)
Chemotherapy
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216)

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer

Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma

The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Real-World Multi-Institutional Analysis

Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma

Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles

Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors

A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy

Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus (SAGE): Results of a Phase II Trial

Evolving landscape of the treatment of metastatic clear cell renal cell carcinoma

Survival outcomes in patients with muscle-invasive bladder cancer receiving neoadjuvant chemotherapy stratified by number of cycles

Real-world outcomes in patients with metastatic clear cell renal cell carcinoma receiving front-line axitinib plus pembrolizumab versus ipilimumab plus nivolumab

Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who receive second-line immunotherapy

Identifying strategies to address obstacles to optimal integration of cancer immunotherapies in the community

Prime-boost immunotherapeutic trial in men with biochemical recurrence after definitive local therapy for prostate cancer

Safety and efficacy of neoadjuvant chemotherapy (NAC) with accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (aMVAC) in patients (pts) with muscle invasive bladder cancer (MIBC) as a function of age

A phase II trial of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN)

Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216)

Multi-center, retrospective study of first-line systemic therapy ± immune checkpoint inhibition for metastatic neuroendocrine carcinoma of the urinary tract

Bicalutamide with or without metformin for biochemical recurrence in prostate cancer patients (BIMET-1)

Role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC)

The evolution of clinical trials in renal cell carcinoma: A status report for 2013-2016 from the clinicaltrials.gov website

Safety of Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer and Malignant Ureteral Obstruction

A phase I/II study of nivolumab and axitinib in patients with advanced renal cell carcinoma

Phase I/II study of axitinib (axi) and nivolumab (nivo) in patients with metastatic renal cell carcinoma (mRCC)

Aktive Filter

Suchergebnisse filtern